On November 3, 2022 Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, reported that five abstracts related to several of its hematology programs have been accepted for poster presentation at the upcoming 64th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, which will be held in New Orleans, LA on December 10-13, 2022 (Press release, Disc Medicine, NOV 3, 2022, View Source [SID1234623057]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to have five abstracts selected for presentation at ASH (Free ASH Whitepaper)," said John Quisel, JD, PhD, Chief Executive Officer at Disc Medicine. "The number of abstracts selected, covering three different Disc programs, demonstrates the breadth of our pipeline and underscores our commitment to addressing unmet needs for patients with serious hematologic conditions."

The full abstracts are now available through the ASH (Free ASH Whitepaper) conference website.